Investigators used electronic medical record data and OSOM® Trichomonas Rapid Tests to assess the prevalence of Trichomonas vaginalis among women attending New York City sexual health clinics in 2016.
Among noninstitutionalized adolescents and adults in the United States between 2013 and 2016, 1.3% tested positive for Trichomonas vaginalis infection.
Less than 60% of prescriptions for the treatment of STIs in adolescents seeking care in emergency departments were filled.
The FDA has granted Breakthrough Device designation to ResistancePlus GC,, a test that detects ciprofloxacin susceptibility.
Persistent human papillomavirus infections may have minimal changes in viral load
The estimated incidence of urogenital infections with chlamydia, gonorrhea, trichomoniasis, and syphilis was 376.4 million in 15- to 49-year-old men and women in 2016.
Less than 60 percent of prescriptions for the treatment of STIs among teens seeking care in the emergency department are filled.
Point-of-care testing may improve infection management in women with urogenital infection, according to a study published in Lancet Infectious Diseases. With an estimated 357 million new curable infections caused by Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Treponema pallidum occuring in 2012, sexually transmitted infections and other urogenital infections are a major disease burden worldwide.…
Ceftriaxone remains the superior first-line treatment for gonorrhea compared with gentamicin.
The FDA has cleared the Aptima Combo 2 Assay (Hologic) and the Xpert CT/NG (Cepheid) to detect chlamydia and gonorrhea via throat and rectum samples.
